# MiNK Therapeutics, Inc.: overview INKT · Nasdaq · CIK 1840229 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/inkt.md) · [Financials](/companies/inkt/financials.md) · [Filings](/companies/inkt/filings.md) · [Insiders](/companies/inkt/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.46)](/filings/0001193125-25-282905.md) | not reported | [(0.70)](/filings/0001193125-26-226804.md) | [(1.06)](/filings/0001193125-26-349309.md) | [(0.65)](/filings/0001193125-25-282905.md) | not reported | [(0.57)](/filings/0001193125-26-226804.md) | [(0.62)](/filings/0001193125-26-349309.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.16)](/filings/0000950170-23-009762.md) | [(0.83)](/filings/0000950170-24-034672.md) | [(6.54)](/filings/0000950170-25-041379.md) | [(2.86)](/filings/0001193125-26-134813.md) | [(2.93)](/filings/0001193125-26-134813.md) | | Free cash flow | $m | [(13.1)](/filings/0000950170-23-009762.md) | [(19.1)](/filings/0000950170-24-034672.md) | [(15.8)](/filings/0000950170-25-041379.md) | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/inkt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $802.6k | 68,660 | | Added +9,296 | | [DNB Asset Management AS](/funds/1456670.md) | 2026-06-30 | $644.6k | 55,142 | | New +55,142 | | [Longbow Finance SA](/funds/1965552.md) | 2026-06-30 | $194.8k | 16,667 | | Unchanged | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $182.1k | 15,573 | | Reduced −1,772 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $180.5k | 15,440 | | New +15,440 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $156.4k | 13,382 | | Added +7,179 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $96.9k | 8,287 | | Unchanged | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $57.1k | 4,885 | | Reduced −10,317 | | [Steward Partners Investment Advisory, LLC](/funds/1723397.md) | 2026-06-30 | $23.4k | 2,000 | | Unchanged | | [US BANCORP \\DE\\](/funds/36104.md) | 2026-06-30 | $23.3k | 1,995 | | New +1,995 | ## Recent filings [All 250 filings](/companies/inkt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-13 | 20:30 ET | [10-Q](/filings/0001193125-26-349309.md) | Quarterly report, period 2026-06-30 | 0001193125-26-349309 | | 2026-08-13 | 11:40 ET | [8-K](/filings/0001193125-26-347907.md) | 2.02 Results of operations | 0001193125-26-347907 | | 2026-06-23 | 14:09 ET | [8-K](/filings/0001193125-26-278642.md) | 5.07 Shareholder vote results | 0001193125-26-278642 | | 2026-05-15 | 20:16 ET | [10-Q](/filings/0001193125-26-226804.md) | Quarterly report, period 2026-03-31 | 0001193125-26-226804 | | 2026-05-15 | 12:03 ET | [8-K](/filings/0001193125-26-225369.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-225369 | | 2026-04-30 | 20:38 ET | [DEF 14A](/filings/0001193125-26-197577.md) | Proxy statement, period 2026-06-17 | 0001193125-26-197577 | | 2026-03-31 | 20:49 ET | [10-K](/filings/0001193125-26-134813.md) | Annual report, period 2025-12-31 | 0001193125-26-134813 | | 2026-03-31 | 12:07 ET | [8-K](/filings/0001193125-26-133346.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-133346 | | 2026-03-27 | 14:40 ET | [8-K](/filings/0001193125-26-127931.md) | 8.01 Other events | 0001193125-26-127931 | | 2026-03-19 | 21:21 ET | [8-K](/filings/0001193125-26-116219.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-116219 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-134813.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1840229 - Tickers: INKT - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.